Moderna Stock Hits Day Low at $24.74 Amid Price Pressure

Moderna, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced significant volatility today, with the stock hitting an intraday low of USD 24.74. The company’s stock has declined by 8.28% as of November 3, 2025, reflecting a challenging performance compared to the S&P 500, which has seen a modest gain of 0.26% on the same day.
Over the past week, Moderna has dropped 6.56%, and its one-month performance shows a decline of 12.57%. The stock's year-to-date performance stands at a notable decrease of 40.09%, while its one-year performance reveals a staggering drop of 54.4%. This trend of underperformance extends over three years, with a decline of 83.11%, significantly lagging behind the S&P 500's growth of 76.66% during the same period.

Financial metrics indicate a challenging landscape for Moderna, with net sales for the latest quarter falling by 82.12% to USD 142 million and a net profit loss of USD 2,916 million over the past nine months. The company also faces rising raw material costs, which have increased by 172.78% year-over-year. These factors contribute to a negative EBITDA and a return on equity of -30.89%, highlighting the ongoing difficulties faced by the company in the current market environment.